Quite an expensive settlement, but a settlement

26/06/20 -"We have taken into account the guided cash out in 2020 and 2021 for the announced settlements of the three litigations. Regarding the 15% tax shield Bayer also guided for, we remain rather more ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

26/06/20

Download

You may also be interested by these reports :

16/04/24

BB Biotech

Preview: Positive 1Q24 driven by clinical developments of portfolio companies

15/04/24

Idea Kicker

Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...

15/04/24

PolyPeptide

Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated

14/04/24

Bayer

We have removed Novo Nordisk from the Bayer peer group since the Danish obesity franchise company has reached a stellar valuation. This has had a ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue